Lorenza Rimassa· @LorenzaRimassa · X·· 2 days agoScore70
Body · original
EileenO’Reilly presents AMPLIFY-7P randomized phase 2 study of adjuvant camupepimut in patients with resected #KRAS-mutant #PDAC at #ESMO26 #ESMOAmbassadors @myESMO
843 views · 17 likes · 6 reposts · 1 reply
Conference abstracts
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org2683Pmatched by NSCLC, metastatic
First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.orgReplies in this thread
- Santhosh Ambika@RenoHemonc
@LorenzaRimassa @myESMO
Source: Lorenza Rimassa · x.com